Alambic Investment Management, L.P. - TETRAPHASE PHARMACEUTICALS I ownership

TETRAPHASE PHARMACEUTICALS I's ticker is TTPHXXXX and the CUSIP is 88165N105. A total of 94 filers reported holding TETRAPHASE PHARMACEUTICALS I in Q1 2018. The put-call ratio across all filers is 0.42 and the average weighting 0.0%.

Quarter-by-quarter ownership
Alambic Investment Management, L.P. ownership history of TETRAPHASE PHARMACEUTICALS I
ValueSharesWeighting
Q1 2019$43,000
-66.9%
32,074
-72.1%
0.02%
-67.3%
Q4 2018$130,000
-46.3%
114,874
+31.0%
0.06%
-71.2%
Q3 2018$242,000
+278.1%
87,704
+392.6%
0.19%
+961.1%
Q2 2018$64,000
-82.0%
17,804
-84.6%
0.02%
-64.0%
Q1 2018$356,000115,8340.05%
Other shareholders
TETRAPHASE PHARMACEUTICALS I shareholders Q1 2018
NameSharesValueWeighting ↓
HARVEY CAPITAL MANAGEMENT INC 354,300$7,068,0002.77%
Opaleye Management Inc. 169,700$3,385,515,0002.64%
Broadfin Capital, LLC 959,247$19,137,0002.01%
Novo Holdings A/S 900,000$17,955,0001.75%
Eventide Asset Management 300,900$6,003,0000.84%
EAM Investors, LLC 152,595$3,044,0000.62%
COLUMBIA PARTNERS L.L.C. INVESTMENT MANAGEMENT 497,858$9,932,0000.51%
Granite Point Capital Management, L.P. 40,000$798,0000.40%
DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) 450,191$8,981,0000.33%
TFS CAPITAL LLC 133,070$2,655,0000.23%
View complete list of TETRAPHASE PHARMACEUTICALS I shareholders